Innovate UK awards grant to Nanna Therapeutics to develop novel drugs

Nanna Therapeutics Ltd has been awarded £829,892 funding from Innovate UK to apply its nanoscale medicines discovery engine to develop novel disease modulating drugs. The discovery engine has the potential to save a considerable amount of time and money facilitating the delivery of cost-effective medicines rapidly which will meet the ever increasing healthcare requirements and costs of an aging population. It also means treating rare and segmented diseases has the potential to become a commercially viable reality, for example Nanna’s lead program targeting Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes, a severe, life-limiting mitochondrial disorder with no effective medicine available to patients.
Nanna Therapeutics’ chief executive officer, Dr. David Williams, said: “The Innovate UK funding will enable us to extend application of our novel drug discovery platform and enable additional corporate growth. Our aim is to address the growing need for effective medicines for diseases associated with an ageing population and mitochondrial dysfunction with a more efficient drug discovery process. It is also a pleasure to welcome Professor David Spring, another supporter of ultimately making the provision of cost-effective treatments for any disease a reality, to our team.”